Skip to main content
Top
Published in: Journal of Clinical Immunology 2/2007

01-03-2007

Immunohistochemical Studies Using Immunized Guinea Pig Sera with Features of Anti-Human Thyroid, Eye and Skeletal Antibody and Graves’ Sera

Authors: IldikÓ MolnÁr, Zita Szombathy, Ilona KovÁcs, A. JÓZsef SzentmiklÓsi

Published in: Journal of Clinical Immunology | Issue 2/2007

Login to get access

Abstract

Type 2 5′ deiodinase enzyme was observed in both thyroid and eye muscle tissues, highlighting its possible role as a common antigen in thyroid-associated ophthalmopathy. Sera of 105 Graves’ patients and 40 controls, and immunized guinea pig sera against TCSS peptide, showing homology to the amino acid sequence from 132 to 152 of type 2 5′ deiodinase, were investigated to demonstrate the binding effects to human thyroid, eye and skeletal muscle tissues.
Twenty-two Graves’ patients were positive for anti-TCSS peptide antibodies, of whom 18 cases had ophthalmopathy. The levels of anti-TCSS peptide antibodies were higher not only in Graves’ patients with (P<0.0001) and without (P<0.036) eye symptoms compared to controls but also the difference was significant between patients with and without ophthalmopathy (P<0.049). In Western blot, immunized sera showed binding reactions to the supernatant fractions of human thyroid, eye and skeletal muscle tissues at the range of 29 kDa. Patient sera with Graves’ ophthalmopathy resulted in positive reactions directed to membrane areas in thyroid follicular cells, and to fibers in eye and skeletal muscles using immunohistochemical method, while no positive staining was present after adding control sera. The binding features of immunized guinea pig sera exhibited similar staining in all human tissues but could be blocked with Graves’ sera. Our results suggest that type 2 5′ deiodinase enzyme protein could play a role as an antigen in Graves’ disease. Immunized guinea pig sera against TCSS peptide exhibited similar binding reactions and stainings to human thyroid, eye and skeletal muscle tissues as patient sera with Graves’ ophthalmopathy.
Literature
1.
go back to reference Bahn RS: Clinical Review 157. Pathophysiology of Graves’ ophthalmopathy. The cycle of disease. J Clin Endocrinol Metab 88:1939–1946, 2003PubMedCrossRef Bahn RS: Clinical Review 157. Pathophysiology of Graves’ ophthalmopathy. The cycle of disease. J Clin Endocrinol Metab 88:1939–1946, 2003PubMedCrossRef
2.
go back to reference Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A: Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385–392, 2002PubMedCrossRef Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A: Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385–392, 2002PubMedCrossRef
3.
go back to reference Takashi Y, Akira S, Ichiro K, Takeo N, Yoshiharu I, Akira T, Sumiya E, Yoshiya T: An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves’ disease. J Clin Endocrinol Metab 85:2775–2778, 2000CrossRef Takashi Y, Akira S, Ichiro K, Takeo N, Yoshiharu I, Akira T, Sumiya E, Yoshiya T: An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves’ disease. J Clin Endocrinol Metab 85:2775–2778, 2000CrossRef
4.
go back to reference Kumar S, Coenen MJ, Scherer PE, Bahn RS: Evidence for enhanced adipogenesis in the orbits of patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 89:930–935, 2004PubMedCrossRef Kumar S, Coenen MJ, Scherer PE, Bahn RS: Evidence for enhanced adipogenesis in the orbits of patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 89:930–935, 2004PubMedCrossRef
5.
go back to reference Mizokami T, Salvi M, Wall JR: Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon? J Endocrinol Invest 27:221–229, 2004PubMed Mizokami T, Salvi M, Wall JR: Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon? J Endocrinol Invest 27:221–229, 2004PubMed
6.
go back to reference Kromminga A, Hagel C, Arndt R, Schuppert F: Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: A possible autoantigenic link in Graves’ patients. J Clin Endocrinol Metab 83:2817–2823, 1998PubMedCrossRef Kromminga A, Hagel C, Arndt R, Schuppert F: Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: A possible autoantigenic link in Graves’ patients. J Clin Endocrinol Metab 83:2817–2823, 1998PubMedCrossRef
7.
go back to reference Gunji K, De Bellis A, Kubota S, Swanson J, Wengrowicz S, Cochran B, Ackrell BAC, Salvi M, Bellastella A, Bizzarro A, Sinisi AA, Wall JR: Serum antibodies against the flavoprotein subunit of eye muscle autoimmunity in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 84:1255–1262, 1999PubMedCrossRef Gunji K, De Bellis A, Kubota S, Swanson J, Wengrowicz S, Cochran B, Ackrell BAC, Salvi M, Bellastella A, Bizzarro A, Sinisi AA, Wall JR: Serum antibodies against the flavoprotein subunit of eye muscle autoimmunity in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 84:1255–1262, 1999PubMedCrossRef
8.
go back to reference Gunji K, De Bellis A, Li AW, Yamada M, Kubota S, Ackrell B, Wengrowicz S, Bellastella A, Bizzarro A, Sinisi A, Wall JR: Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: Autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 85:1641–1647, 2000PubMedCrossRef Gunji K, De Bellis A, Li AW, Yamada M, Kubota S, Ackrell B, Wengrowicz S, Bellastella A, Bizzarro A, Sinisi A, Wall JR: Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: Autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 85:1641–1647, 2000PubMedCrossRef
9.
go back to reference De Bellis A, Sansone D, Coronella C, Conte M, Iorio S, Perrino S, Battaglia M, Bellastella G, Wall JR, Bellastella A, Bizzarro A: Serum anibodies to collagen XIII: A futher good marker of active Graves’ ophthalmopathy. Clin Endocrinol 62:24–29, 2005CrossRef De Bellis A, Sansone D, Coronella C, Conte M, Iorio S, Perrino S, Battaglia M, Bellastella G, Wall JR, Bellastella A, Bizzarro A: Serum anibodies to collagen XIII: A futher good marker of active Graves’ ophthalmopathy. Clin Endocrinol 62:24–29, 2005CrossRef
10.
go back to reference Gopinath B, Musselman R, Adams CL, Tani J, Beard N, Wall JR: Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves’ disease with and without ophthalmopathy: Correlation with clinical features. Thyroid 16:967–974, 2006.PubMedCrossRef Gopinath B, Musselman R, Adams CL, Tani J, Beard N, Wall JR: Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves’ disease with and without ophthalmopathy: Correlation with clinical features. Thyroid 16:967–974, 2006.PubMedCrossRef
11.
go back to reference Tani J, Wall JR: Autoimmunity against eye-muscle antigens may explain thyroid-associated ophthalmopathy. CMAJ 175:239–241, 2006PubMed Tani J, Wall JR: Autoimmunity against eye-muscle antigens may explain thyroid-associated ophthalmopathy. CMAJ 175:239–241, 2006PubMed
12.
go back to reference Salvatore D, Tu H, Harney JW, Larsen PR: Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest 98:962–968, 1996PubMedCrossRef Salvatore D, Tu H, Harney JW, Larsen PR: Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest 98:962–968, 1996PubMedCrossRef
13.
go back to reference Hosoi Y, Murakami M, Mizuma H, Ogiwara T, Imamura M, Mori M: Expression and regulation of type II iodothyronine deiodinase in cultured human skeletal muscle cells. J Clin Endocrinol Metab 84:3293–3300, 1999PubMedCrossRef Hosoi Y, Murakami M, Mizuma H, Ogiwara T, Imamura M, Mori M: Expression and regulation of type II iodothyronine deiodinase in cultured human skeletal muscle cells. J Clin Endocrinol Metab 84:3293–3300, 1999PubMedCrossRef
14.
go back to reference Croteau W, Davey JC, Galton VA, Germain LSt: Cloning of the mammalian type II iodothyronine deiodinase. J Clin Invest 98:405–417, 1996PubMed Croteau W, Davey JC, Galton VA, Germain LSt: Cloning of the mammalian type II iodothyronine deiodinase. J Clin Invest 98:405–417, 1996PubMed
15.
go back to reference Merrifield RB: The synthesis of a tetrapeptide. Solid phase peptide synthesis. J Am Chem Soc 85:2149–2154, 1963CrossRef Merrifield RB: The synthesis of a tetrapeptide. Solid phase peptide synthesis. J Am Chem Soc 85:2149–2154, 1963CrossRef
16.
go back to reference Matsueda GR, Stewart JM: A p-ethylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides. Peptides 2:45–50, 1981PubMedCrossRef Matsueda GR, Stewart JM: A p-ethylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides. Peptides 2:45–50, 1981PubMedCrossRef
17.
go back to reference Sakakibara S, Shimonishim Y, Kishida Y, Okada M, Sugihara K: Use of anhydrous hydrogen fluoride in peptide synthesis. I. Behavior of various protective groups in anhydrous hydrogen fluoride. Bull Chem Soc Jpn 40:2164–2167, 1967PubMedCrossRef Sakakibara S, Shimonishim Y, Kishida Y, Okada M, Sugihara K: Use of anhydrous hydrogen fluoride in peptide synthesis. I. Behavior of various protective groups in anhydrous hydrogen fluoride. Bull Chem Soc Jpn 40:2164–2167, 1967PubMedCrossRef
18.
go back to reference Werner SC: Modification of classification of eye changes of Graves’ disease: Recommendations of the Ad Hoc Committee of American Thyroid Association. J Clin Endocrinol Metab 44:2034, 1977CrossRef Werner SC: Modification of classification of eye changes of Graves’ disease: Recommendations of the Ad Hoc Committee of American Thyroid Association. J Clin Endocrinol Metab 44:2034, 1977CrossRef
19.
go back to reference Mourits PM, Prummel ME, Wiersinga WM, Kornneef L: Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxford) 47:9–14, 1997CrossRef Mourits PM, Prummel ME, Wiersinga WM, Kornneef L: Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxford) 47:9–14, 1997CrossRef
20.
go back to reference Bradford MM: A rapid and sensitive method for the qualification of microgram quantites of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254, 1976PubMedCrossRef Bradford MM: A rapid and sensitive method for the qualification of microgram quantites of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254, 1976PubMedCrossRef
21.
go back to reference Molnar I., Kaczur V., Boros A., Krajczar G., Balzs C.: IgA autoantibodies against human eye muscle antigen detected by Western blotting and immunohistochemical methods in Graves’ disease. J Endocrinol Invest 18:408–414, 1995PubMed Molnar I., Kaczur V., Boros A., Krajczar G., Balzs C.: IgA autoantibodies against human eye muscle antigen detected by Western blotting and immunohistochemical methods in Graves’ disease. J Endocrinol Invest 18:408–414, 1995PubMed
22.
go back to reference Darras VM, Hume R, Visser TJ: Regulation of thyroid hormone metabolism during fetal development. Mol Cell Endocrinol 151:37–47, 1999PubMedCrossRef Darras VM, Hume R, Visser TJ: Regulation of thyroid hormone metabolism during fetal development. Mol Cell Endocrinol 151:37–47, 1999PubMedCrossRef
23.
go back to reference Köhrle J: Local activation and inactivation of thyroid hormones: The deiodinase family. Mol Cell Endocrinol 151:103–119, 1999PubMedCrossRef Köhrle J: Local activation and inactivation of thyroid hormones: The deiodinase family. Mol Cell Endocrinol 151:103–119, 1999PubMedCrossRef
24.
go back to reference Molnar I, Csathy L: Autoantibodies against the type 2 5′-deiodinase are involved in the development of Graves’ ophthalmopathy. In Program of 12th international Thyroid Congress, Kyoto, Japan, p 176 (Abstract), 2000 Molnar I, Csathy L: Autoantibodies against the type 2 5′-deiodinase are involved in the development of Graves’ ophthalmopathy. In Program of 12th international Thyroid Congress, Kyoto, Japan, p 176 (Abstract), 2000
25.
go back to reference Nakahara R, Tsunekawa K, Yabe S, Nara M, Seki K, Kasahara T, Ogiwara T, Nishino M, Kobayashi I, Murakami M: Association of antipitiutary antibody and type 2 iodothyronine deiodinase antibody in patients with autoimmune thyroid disease. Endocrinol J 52:691–699, 2005 Nakahara R, Tsunekawa K, Yabe S, Nara M, Seki K, Kasahara T, Ogiwara T, Nishino M, Kobayashi I, Murakami M: Association of antipitiutary antibody and type 2 iodothyronine deiodinase antibody in patients with autoimmune thyroid disease. Endocrinol J 52:691–699, 2005
26.
go back to reference Stadtman TC: Selenoproteins—tracing the role of a trace element in protein function. PloS Biol 3:2077–2079, 2005CrossRef Stadtman TC: Selenoproteins—tracing the role of a trace element in protein function. PloS Biol 3:2077–2079, 2005CrossRef
27.
go back to reference Gereben B, Goncalves C, Harney JW, Larsen PR, Bianco AC: Selective proteolysis of human type 2 deiodinase: A novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol Endocrinol 14:1697–1708, 2000PubMedCrossRef Gereben B, Goncalves C, Harney JW, Larsen PR, Bianco AC: Selective proteolysis of human type 2 deiodinase: A novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol Endocrinol 14:1697–1708, 2000PubMedCrossRef
28.
go back to reference Zeöld A, Pormüller L, Dentice M, Harney JW, Curcio-Morelli C, Tente SM, Bianco AC, Gereben B: Metabolic instability of type 2 deiodinase is transferable to stable proteins independently of subcellular localization. J Biol Chem 281:31538–31543, 2006PubMedCrossRef Zeöld A, Pormüller L, Dentice M, Harney JW, Curcio-Morelli C, Tente SM, Bianco AC, Gereben B: Metabolic instability of type 2 deiodinase is transferable to stable proteins independently of subcellular localization. J Biol Chem 281:31538–31543, 2006PubMedCrossRef
29.
go back to reference Burmeister LA, Pachucki J, St. Germain DL: Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. Endocrinology 138:5231–5237, 1997PubMedCrossRef Burmeister LA, Pachucki J, St. Germain DL: Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. Endocrinology 138:5231–5237, 1997PubMedCrossRef
30.
go back to reference Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR: Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme’s active center. Endocrinology 141:1127–1135, 2000PubMedCrossRef Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR: Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme’s active center. Endocrinology 141:1127–1135, 2000PubMedCrossRef
31.
go back to reference Kaminski HJ, Li Z, Richmonds C, Ruff RL, Kusner L: Susceptibility of ocular tissues to autoimmune diseases. Ann NY Acad Sci 998:362–374, 2003PubMedCrossRef Kaminski HJ, Li Z, Richmonds C, Ruff RL, Kusner L: Susceptibility of ocular tissues to autoimmune diseases. Ann NY Acad Sci 998:362–374, 2003PubMedCrossRef
32.
go back to reference Andrikoula M, Tsatsoulis A: The role of FAS-mediated apoptosis in thyroid disease. Eur J Endocrinol 144:561–568, 2001PubMedCrossRef Andrikoula M, Tsatsoulis A: The role of FAS-mediated apoptosis in thyroid disease. Eur J Endocrinol 144:561–568, 2001PubMedCrossRef
33.
go back to reference Pittoni V, Valesini G: The clearence of apoptotic cells: Implications for autoimmunity. Autoimmunity Rev 1:154–161, 2002CrossRef Pittoni V, Valesini G: The clearence of apoptotic cells: Implications for autoimmunity. Autoimmunity Rev 1:154–161, 2002CrossRef
34.
go back to reference Salvatore D, Bartha T, Harney JW, Larsen PR: Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 137:3308–3315, 1996PubMedCrossRef Salvatore D, Bartha T, Harney JW, Larsen PR: Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 137:3308–3315, 1996PubMedCrossRef
Metadata
Title
Immunohistochemical Studies Using Immunized Guinea Pig Sera with Features of Anti-Human Thyroid, Eye and Skeletal Antibody and Graves’ Sera
Authors
IldikÓ MolnÁr
Zita Szombathy
Ilona KovÁcs
A. JÓZsef SzentmiklÓsi
Publication date
01-03-2007
Published in
Journal of Clinical Immunology / Issue 2/2007
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-006-9063-x

Other articles of this Issue 2/2007

Journal of Clinical Immunology 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.